European Journal of Internal Medicine
Volume 20, Issue 1 , Pages 3-8 , January 2009

Physician's guide to pharmacovigilance: Terminology and causality assessment

  • H.S. Rehan

      Affiliations

    • Department of Pharmacology, Lady Hardinge Medical College, New Delhi 110001, India
    • National Pharmacovigilance Programme, Lady Hardinge Medical College, New Delhi 110001, India
    • ,
  • Deepti Chopra

      Affiliations

    • Department of Pharmacology, Lady Hardinge Medical College, New Delhi 110001, India
    • Corresponding Author InformationCorresponding author. Tel.: +91 9818710237.
    • ,
  • Ashish Kumar Kakkar

      Affiliations

    • Department of Pharmacology, Lady Hardinge Medical College, New Delhi 110001, India

Received 16 August 2007 ,Revised 29 March 2008 ,Accepted 25 April 2008.

References 

  1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. JAMA. 1998;279:1200–1205
  2. Bord CA, Rachl CL. Adverse drug reactions in United States hospitals. Pharmacotherapy. 2006;26(5):601–608
  3. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–245
  4. Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR. An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. JAMA. 1979;242:623–632
  5. Karch FE, Lasagna L. Adverse drug reactions: a critical review. JAMA. 1975;234:1236–1241
  6. The use of the WHO–UMC system for standardised case causality assessment. Accessed at www.who-umc.org/graphics/4409.pdf on 15 June 2007.
  7. World Health Organization Collaborating Center for International Drug Monitoring . The importance of pharmacovigilance. Safety monitoring of medicinal products. Geneva: World Health Organization; 2002;
  8. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255–1259
  9. Clinical safety data management: definitions and standards for expedited reporting. London: European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit; 1995;Accessed at www.emea.eu.int/pdfs/human/ich/037795en.pdf
  10. Cobert BL, Biron P. Pharmacovigilance from A to Z. Malden, MA: Blackwell Science; 2002;
  11. What is a medication error?. Rockville, MD: National Coordinating Council for Medication Error Reporting and Prevention; 1998;Accessed at www.nccmerp.org.
  12. Bates DW. Medication errors. How common are they and what can be done to prevent them?. Drug Saf. 1996;15:303–310
  13. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995;274:29–34
  14. Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Saf. 1994;10:93–102
  15. Kumar P, Clark M. Clinical medicine. 6th ed.. Elseviers Saunders; 2005;
  16. WHO safety of medicines. A guide to detecting and reporting adverse drug reactions. Why health professionals need to take action. Geneva: World Health Organization; 2002;WHO/EDM/QSM/2002.2
  17. Wiholm BE, Olsson S, Moore N, Waller P. Spontaneous reporting systems outside the United States. In:  Strom BL editors. Pharmacoepidemiology. 3rd edn. Chichester: Wiley; 2000;p. 175–192
  18. Vallano A, Cereza G, Pedros C, Agusti A, Danes I, Aguilera C, et al. Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital. Br J Clin Pharmacol. 2005;60:653–658
  19. Brown SD, Landry FJ. Recognizing, reporting and reducing adverse drug reactions. South Med J. 2001;94:370–373

PII: S0953-6205(08)00129-5

doi: 10.1016/j.ejim.2008.04.019

European Journal of Internal Medicine
Volume 20, Issue 1 , Pages 3-8 , January 2009

Article Tools